Surgery – Diagnostic testing – Measuring or detecting nonradioactive constituent of body...
Reexamination Certificate
2000-10-19
2003-02-18
Hindenburg, Max F. (Department: 3736)
Surgery
Diagnostic testing
Measuring or detecting nonradioactive constituent of body...
C600S322000, C600S365000
Reexamination Certificate
active
06522903
ABSTRACT:
FIELD OF THE INVENTION
This invention involves non-invasive glucose measurement and a process for determining blood glucose levels in the human body. Preferably, the process is used on a fingertip or other part of the body, typically a skin surface of the body.
BACKGROUND OF THE INVENTION
The American Diabetes Association reports that nearly 6% of the population in the United States, a group of 16 million people, has diabetes. The Association further reports that diabetes is the seventh leading cause of death in the United States, contributing to nearly 200,000 deaths per year. Diabetes is a chronic disease having no cure. The complications of the disease include blindness, kidney disease, nerve disease, and heart disease, perhaps with stroke. Diabetes is said to be the leading cause of new cases of blindness in individuals in the range of ages between 20 and 74; from 12,000-24,000 people per year lose their sight because of diabetes. Diabetes is the leading cause of end-stage renal disease, accounting for nearly 40% of new cases. Nearly 60-70% of people with diabetes have mild to severe forms of diabetic nerve damage which, in severe forms, can lead to lower limb amputations. People with diabetes are 2-4 times more likely to have heart disease and to suffer strokes.
Diabetes is a disease in which the body does not produce or properly use insulin, a hormone needed to convert sugar, starches, and the like into energy. Although the cause of diabetes is not completely understood, genetics, environmental factors, and viral causes have been partially identified.
There are two major types of diabetes: Type I and Type II. Type I diabetes (formerly known as juvenile diabetes) is an autoimmune disease in which the body does not produce any insulin and most often occurs in young adults and children. People with Type I diabetes must take daily insulin injections to stay alive.
Type II diabetes is a metabolic disorder resulting from the body's inability to make enough, or properly to use, insulin. Type II diabetes accounts for 90-95% of diabetes. In the United States, Type II diabetes is nearing epidemic proportions, principally due to an increased number of older Americans and a greater prevalence of obesity and a sedentary lifestyle.
Insulin, in simple terms, is the hormone that unlocks the cells of the body, allowing glucose to enter those cells and feed them. Since, in diabetics, glucose cannot enter the cells, the glucose builds up in the blood and the body's cells literally starve to death.
Diabetics having Type I diabetes typically are required to self-administer insulin using, e.g., a syringe or a pin with needle and cartridge. Continuous subcutaneous insulin infusion via implanted pumps is also available. Insulin itself is typically obtained from pork pancreas or is made chemically identical to human insulin by recombinant DNA technology or by chemical modification of pork insulin. Although there are a variety of different insulins for rapid-, short-, intermediate-, and long-acting forms that may be used variously, separately or mixed in the same syringe, use of insulin for treatment of diabetes is not to be ignored.
It is highly recommended by the medical profession that insulin-using patients practice self-monitoring of blood glucose (SMBG). Based upon the level of glucose in the blood, individuals may make insulin dosage adjustments before injection. Adjustments are necessary since blood glucose levels vary day to day for a variety of reasons, e.g., exercise, stress, rates of food absorption, types of food, hormonal changes (pregnancy, puberty, etc.) and the like. Despite the importance of SMBG, several studies have found that the proportion of individuals who self-monitor at least once a day significantly declines with age. This decrease is likely due simply to the fact that the typical, most widely used, method of SMBG involves obtaining blood from a finger stick. Many patients consider obtaining blood to be significantly more painful than the self-administration of insulin.
There is a desire for a less invasive method of glucose measurement. Methods exist or are being developed for a minimally invasive glucose monitoring, which use body fluids other than blood (e.g., sweat or saliva), subcutaneous tissue, or blood measured less invasively. Sweat and saliva are relatively easy to obtain, but their glucose concentration appears to lag in time significantly behind that of blood glucose. Measures to increase sweating have been developed and seem to increase the timeliness of the sweat glucose measurement, however.
Subcutaneous glucose measurements seem to lag only a few minutes behind directly measured blood glucose and may actually be a better measurement of the critical values of glucose concentrations in the brain, muscle, and in other tissue. Glucose may be measured by non-invasive or minimally-invasive techniques, such as those making the skin or mucous membranes permeable to glucose or those placing a reporter molecule in the subcutaneous tissue. Needle-type sensors have been improved in accuracy, size, and stability and may be placed in the subcutaneous tissue or peripheral veins to monitor blood glucose with small instruments. See,
“An Overview of Minimally Invasive Technologies”,
Clin. Chem. September 1992; 38(9):1596-1600.
Truly simple, non-invasive methods of measuring glucose are not commercially available.
SUMMARY OF THE INVENTION
This invention involves non-invasive glucose measurement and a process for determining blood glucose levels in the human body upon achieving a static level of glucose at a skin surface over a period of time.
Processes which are able to assess glucose concentrations predictably from a skin surface may include a step of extracting a sample from the skin and then measuring that sample from the skin. Such sample extraction processes may include suction blister extraction, wick extraction, microdialysis extraction, iontophoretic extraction, sontophoretic extraction, and chemically enhanced extraction. Aside from the extraction processes, non-invasive measurement processes may include electrochemical sensors (e.g., glucose electrodes), optochemical sensors (e.g., colorimetric strips), near-infrared spectroscopy (NIR), mid-infrared spectroscopy (MIR), infrared spectroscopy (IR), Raman spectroscopy, photoacoustic spectroscopy, measurement of refractive index or scatter changes, fluorescent spectroscopy, and polarization spectroscopy.
The processes for extraction and measurement are illustrative and are not meant to be an exclusive list.
REFERENCES:
patent: 4169676 (1979-10-01), Kaiser
patent: 4427889 (1984-01-01), Müller
patent: 4538618 (1985-09-01), Rosenberg et al.
patent: 4655255 (1987-04-01), Rode
patent: 4710231 (1987-12-01), Bateman et al.
patent: 4821733 (1989-04-01), Peck
patent: 4909256 (1990-03-01), Peck
patent: 5028787 (1991-07-01), Rosenthal et al.
patent: 5036861 (1991-08-01), Sembrowich et al.
patent: 5086229 (1992-02-01), Rosenthal et al.
patent: 5115133 (1992-05-01), Knudson
patent: 5178142 (1993-01-01), Harjunmaa et al.
patent: 5179951 (1993-01-01), Knudson
patent: 5267152 (1993-11-01), Yang et al.
patent: 5313941 (1994-05-01), Braig et al.
patent: 5341805 (1994-08-01), Stavridi et al.
patent: 5390238 (1995-02-01), Kirk et al.
patent: 5398681 (1995-03-01), Kupershmidt
patent: 5433197 (1995-07-01), Stark
patent: 5470323 (1995-11-01), Smith et al.
patent: 5582184 (1996-12-01), Erickson et al.
patent: 5638815 (1997-06-01), Shoendorfer
patent: 5682233 (1997-10-01), Brinda
patent: 5749217 (1998-05-01), Etheridge
patent: 5754289 (1998-05-01), Ozaki et al.
patent: 5820570 (1998-10-01), Erickson et al.
patent: 5879310 (1999-03-01), Sopp et al.
patent: 5879367 (1999-03-01), Latterell et al.
patent: 5890489 (1999-04-01), Elden
patent: 5941821 (1999-08-01), Chou
patent: 6001067 (1999-12-01), Shults et al.
patent: 6087182 (2000-07-01), Jeng et al.
patent: 6149588 (2000-11-01), Noda et al.
patent: 6152875 (2000-11-01), Hakamata
patent: 6188477 (2001-02-01), Pu et al.
patent: 0 329 361 (1989-08-01), None
patent: WO 96/19180
Berman Herbert L.
Blair Robert N.
Roe Jeffrey N.
Hindenburg Max F.
Kremer Matthew
MedOptix, Inc.
Morrison & Foerster / LLP
LandOfFree
Glucose measurement utilizing non-invasive assessment methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucose measurement utilizing non-invasive assessment methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucose measurement utilizing non-invasive assessment methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3170954